spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  vaginal cancer 

 HSMN NewsFeed - 22 Dec 2010
US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Feb 2010
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2009
FDA Approves GARDASIL(R) for Use in Boys and Young Men
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jan 2009
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2008
Supplemental Application for GARDASIL(R), Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
Biopharmaceuticals
 HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2007
Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
Oncology
 HSMN NewsFeed - 20 Jun 2007
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2007
Data Published in The Lancet Show GARDASIL(R) was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Merck Submits New Cross-Protection Data for GARDASIL(R) to the FDA and Seeks New Indications for Vaginal and Vulvar Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 May 2006
FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
vaginal cancer
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!